My research to develop a cure for Malaria began over 8 years ago when my wife, Bonita, and I conducted medical missions in Port-du-Prince, Haiti. At a Christian orphanage directed by Roberta Audate, we observed malaria for the first time. Having seen the advantages of using low dose chemotherapy drugs in treating cancer, where the immune system remains intact and active against the cancer, I decided to help Roberta with the children in her care by giving them low dose PeroxyBioFlavonoids. We used an extended time of 16 days in the hope of immunizing the patients against the malaria by transitioning through the IgM/IgG maturation and stimulating whatever innate immunity that may also play a role. With Haitian governmental approval for a time, we were able to follow the effects of my treatment over the years in over 500 people. Though not using the normal protocol for a scientific study, this group included a close knit community of 15 churches. Furthermore, Children were selected and followed from a daily feeding program conducted by Roberta with over 165 children, including Roberta’s 20+ children who lived at her house. We saw no failures.
Dr. Jerry Thornthwaite
CuringAndPreventing.com
Harel Insurance & Finance Ltd, Israel’s leading firm in health insurance, and Harel-Yedidim, the overseas division of Yedidim Ltd., are pleased to welcome you to Israel. Our team will help you to enjoy a professional service and assistance 24 hours a day.
Our services will be provided by the Clalit Health Services, which has clinics throughout Israel. You may choose to register with one of them and make it your home clinic. The magnetic card that you receive from Clalit must be presented in order for you to receive health services, medication or tests. Please make sure to carry your magnetic card on you at all times.
Harel Insurance & Finance Ltd, Israel’s leading firm in health insurance, and Harel-Yedidim, the overseas division of Yedidim Ltd., are pleased to welcome you to Israel. Our team will help you to enjoy a professional service and assistance 24 hours a day.
Our services will be provided by the Clalit Health Services, which has clinics throughout Israel. You may choose to register with one of them and make it your home clinic. The magnetic card that you receive from Clalit must be presented in order for you to receive health services, medication or tests. Please make sure to carry your magnetic card on you at all times.
Chair, Charles Vega, MD, FAAFP, prepared useful Practice Aids pertaining to influenza for this CME/MOC/NCPD activity titled “Examining Novel Approaches to Improve the Management of Influenza: An Animated Exploration.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/31FYp8J. CME/MOC/NCPD credit will be available until July 20, 2022.
SImplified Malaria overview for practising pediatricians in India - north india more specifically with a low incidence of malaria. By Dr Gaurav Gupta MD Pediatrician, Charak Clinics, Mohali, Chandigarh
Speakers discuss PrEP counseling, special situations, and other topics covered in training modules three and four. During this webinar, expert speakers review key highlights from modules three and four, and respond to questions from participants.
Part one: https://www.slideshare.net/jsi/prep-elearning-discussion-i
National Aspergillosis Centre Doctor Livingstone Chishimba holds a Q&A sessionGraham Atherton
Livingstone Chishimba specialises in aspergillosis (amongst other things) and works at the National Aspergillosis Centre, Manchester, UK.
This is a regular monthly support meeting held at the NAC for patients living with aspergillosis.
Canadian Medical community is as shocked and surprised as Cystinosis Patient Families. The Health Canada decision to remove choice from our system while increasing cost of a small patient group of 70 by $50M annually is negligent. Horizon Pharmaceutical Procysbi has a spot in the line up, it just shouldn't be the default or only option when Cystinosis patients in Canada have been well managed for since Mylan Cystagon was used to start treating it back in 1994.
Thank you very much for the invitation to address my fellow colleagues and troops who have taken up arms in one of the greatest wars of our area- the battle with the unseen enemy Coronavirus.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Chair, Charles Vega, MD, FAAFP, prepared useful Practice Aids pertaining to influenza for this CME/MOC/NCPD activity titled “Examining Novel Approaches to Improve the Management of Influenza: An Animated Exploration.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at https://bit.ly/31FYp8J. CME/MOC/NCPD credit will be available until July 20, 2022.
SImplified Malaria overview for practising pediatricians in India - north india more specifically with a low incidence of malaria. By Dr Gaurav Gupta MD Pediatrician, Charak Clinics, Mohali, Chandigarh
Speakers discuss PrEP counseling, special situations, and other topics covered in training modules three and four. During this webinar, expert speakers review key highlights from modules three and four, and respond to questions from participants.
Part one: https://www.slideshare.net/jsi/prep-elearning-discussion-i
National Aspergillosis Centre Doctor Livingstone Chishimba holds a Q&A sessionGraham Atherton
Livingstone Chishimba specialises in aspergillosis (amongst other things) and works at the National Aspergillosis Centre, Manchester, UK.
This is a regular monthly support meeting held at the NAC for patients living with aspergillosis.
Canadian Medical community is as shocked and surprised as Cystinosis Patient Families. The Health Canada decision to remove choice from our system while increasing cost of a small patient group of 70 by $50M annually is negligent. Horizon Pharmaceutical Procysbi has a spot in the line up, it just shouldn't be the default or only option when Cystinosis patients in Canada have been well managed for since Mylan Cystagon was used to start treating it back in 1994.
Thank you very much for the invitation to address my fellow colleagues and troops who have taken up arms in one of the greatest wars of our area- the battle with the unseen enemy Coronavirus.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
5. Malaria Treatment
What is Malaria?
History of MalariaTreatments
What PeroxyBioFlavonoid™?
How does it work?
Our Research
Sources of Artemisinin
6. What is Malaria?
Parasitic disease of red blood cells
Mosquito carrier
225 Million cases in 2009
1.28 Million deaths in 2010
Haiti
30,000 reportedCDC
200,000 unreported CDC
Haiti has the most dangerous type
of malaria...Plasmodium falciparum.
7. History of Malaria Treatments
200 BC China SweetWormwood
1997 Chinese isolated the Artemisinin
They did not reveal it until recent years
Current Drugs – chloroquine, atovaquone-proguanil (Malarone®)
artemether-lumefantrine (Coartem®), mefloquine (Lariam®), quinine, quinidine
doxycycline (used in combination with quinine)
clindamycin (used in combination with quinine)
Artemether-lumefantrine (Coartem®) FDA
not approved for patients with severe or complicated P. falciparum malaria.
not approved for the prevention of malaria
Artemisinin is safe with minimum side effects as stated by FDA
However, Artemisinin alone is not enough
8. PeroxyBioFlavonoid™Peroxide Bridge
How it Kills the Parasites
Malaria parasite breaks down Hemaglobulin
and releases iron. The peroxide causes a free
radical chain of events initiated by the Fe and
also within the mitochondria that destroy the
parasite. The BioFlavonoid inhibits three
enzymes in the intestines that can breakdown
Artemisinin and provides antioxidant activity to
immune cells
Protection from Malaria Recurrence (Theory)
■ Rapid release of malaria proteins as antigen source
■ So-called “Super Antigens” with apoptotic parasites and
adjuvant effects
■ Natural KillerCell Function
■ Most Effective Antibodies, IgG1 and IgG3
■ Minimize Pro-inflammatory Cytokines (IFN,TNF, IL1) to avoid
severe pathology
■ Boost the Immunity with supplements taken during the trials
9. PeroxyBioFlavonoid™ Capsules
Simple, Oral Dose (one 50mg tablet for children with two
tablets for each of 16 days)
Fast symptom relief (2-3 days)
Dramatic Clearance (95% parasite clearance within 2-3
Days)
No Recurrences (Haiti none in over 600 cases; or 92 cases
in Nigeria to date)
Inexpensive
Proven in clinicals in Haiti and Nigeria
Patented process to prevent capsule dissolving
in the stomach
11. Haiti Minister of Health, Dr. Charles, Harry
Hames of Helping Hands International, Roberta
and Malaria Treatment approval
Roberta
Minister of
Health
Dr. Charles
Bonita
Mr..Hames
17. NigerianClinical and Economic Approval
PROTOCOL FOR THE STUDY OF PEROXYBIOFLAVONOID IN THE
TREATMENT OF MALARIA IN SOUTH-WESTERN NIGERIA
The goals of this Human Subjects study are to determine the overall
curative rate of Plasmodium falciparum in 70 patients and determine
the mechanism of action in serum samples obtained from them.
The Principal Investigators:
Dr. Olufemi Akanni, Department of Biomedical Sciences, College of Health Sciences,
(Mercyland Campus) Dada Estate, Osogbo. Osun - State. Nigeria.
Dr. Jerry T. Thornthwaite, Director, Cancer Research Institute of West Tennessee,
114 East Main Street, Henderson, USA.
Study Clinician & Co-Investigator:
Dr. Akeem Ayankunle, Head of Malaria Research Laboratory,
Department of Pharmacology & Therapeutics, Ladoke Akintola University of Technology
(Isale-Osun Campus), Osogbo, Osun State. Mobile: 08061670022.
The final study actually included 112 Patients
18.
19. Progress Reports from Nigeria 4-5-15
Dear Prof. Compliment of the Easter season to you and family. You are
welcome back from Haiti.
I am glad to inform you that we started the study last month and also
to tell you that the antimalarial formulation is performing amazingly
well on the malaria patients so far recruited. The patients appear to
recover fast from pyrexia and even get well fast. As far as the study
is concerned, the recruitment process is slow owing to some reasons
from our strict exclusion criteria:
- Most patients are already on one form of antimalarial drug/treatment
before coming
to the health facilities we are using hence excluded (most
drugs are not efficient or
malaria parasites are resistant to them).
- Some patients complain about the long duration of treatment hence
not ready to give
consent.
- Some patients have low parasitemia load hence not recruitable since
we want those
with severe form of malaria for the study.
- Also, the raining season when cases of malaria infection is very
high is just starting
(ie moving from dry season to raining) in the tropical countries.
- Some health facilities are on industrial action due to unpaid salaries.
However, we are trying to connect another big health facility with our
approval to commence the study to increase chances of fast recruitment
this week after Easter break.
So far we have recruited only 7 patients which we hope to improve
tremendously from next week. This slow pace has caused delay or
prolonged duration of the study than proposed.
I belief we are getting good results and much more when you carry out
immunological assays hopefully. I’m sure this is going to be a major
breakthrough in antimalarial treatment to save millions of patients in
Africa and other malaria endemic countries.
Thank you, Olufemi
20. Progress Reports from Nigeria 4-24-15
Dear Prof. No doubt, the antimalarial treatment is working and I want to belief that the serum
immunologic testings will support our claim and provide reason for no further occurrence of malaria
infection in patients. Please keep working on possibility of reducing the treatment duration of 16 days
possibly before it hits the African huge market soon.
We hope recruitment will keep improving as we start moving into raining season.
Thanks.
OLUFEMI.
Progress Reports from Nigeria 5-1-15 & 5-9-15 & 5-24-15
5-1-15
Dear Prof.
I'm glad to inform you that as at today we have recruited 35 patients with 3 lost to follow-up. The patients are doing well.
Warm regards. Olufemi.
5-9-15
Till date we have recruited 76 patients into the study in Nigeria with
4 individuals lost to follow up. Also, we recorded 3 cases of relapse
after day 30 when the patients reported for blood collection with high
fever and tested positive for malaria parasites. We are feeling the
relapse could be due to possible under dose of the formulation which
could also be due to the infants not taking the complete formulation
in the capsule.
I am also planning packaging and courier dispatch of the first batch
of sera obtained so far to your laboratory.
Kindly respond to the relapse cases and any update on the formulation.
Our plan is to continue recruitment to about 90 -100 to cater for
those that could be lost to follow up till day 60.
Our fund/cash is running low kindly start the process of crediting us.
Thank you. Olufemi.
5-24-15
Please may I know what the inventory list should contain?
Alright. I'll work on sending the Sera available so far.
Further
updates to follow soon.
Olufemi
21. 5-13-15
STUDY PROGRESS REPORTS
First one on Easter Sunday with an Easter salutation from my Nigerian Christian
Medical Scientists:
Dear Prof.The antimalarial study is progressing. I'm happy to inform you that the
formulation is working fantastically well on Nigerian patients. No disappointment
so far. Despite the adverse conditions highlighted in the last progress report, we
have recruited 15 patients with our strict inclusion /exclusion criteria. Blood had
been drawn to day 30 in the initial patients awaiting day 60 & final collection.
10 days later:
Dear Prof. No doubt, the antimalarial treatment is working and I want to belief
that the serum immunologic testings will support our claim and provide reason for
no further occurrence of malaria infection in patients. Please keep working on
possibility of reducing the treatment duration of 16 days possibly before it hits the
African huge market soon.
We hope recruitment will keep improving as we start moving into raining season.
Thanks.
OLUFEMI.
25. Table 2
Children with Recurrent Malaria
LAB NO Age Sex Day 0 Day 1 Day 2 Day 3 Day 7 Day 14 Day 30 Result
PF/011 5 f 55120 4240 0 2880 2400 Failed
PF/065 7 f 50920 10480 1240 480 0 0 28960 Failed
Pf018 8 f 16440 4560 520 0 0 0 8640 Failed
Pf025 12 f 2040 160 0 0 0 0 22160 Failed
PF/018 5 m 69920 2160 8040 Failed
PF/030 7 m 17040 3480 560 0 0 0 32160 Failed
PF/032 12 m 2760 0 0 4840 Failed
PF/043† 10 m 15560 3840 0 0 0 0 4360 Failed
PF/044† 7 m 12560 1480 0 0 6680 Failed
PF/045† 9 m 4360 720 0 0 0 3240 Failed
Pf006 9 m 4640 520 0 0 0 0 4680 Failed
n=11 8.3 22851 3276 387 60 0 504 11469
2.4 24060 3200 495 170 0 1076 10870
†PF/43-45 all males from the same family
26. Table 3
Statistical Data from the Children Treated with the MALSUP™
Average Malaria Parasite Load MPL) at Day 0 Cured: 20,224 ± 26339 SD Recurrent: 22,851 ± 24,060
Average Age of the Patients: Cured: 8.4 ± 3.6 Recurrent: 8.3 ± 2.4
Percentage of Males – Cured: 55.4%
Cure Rate – 90.2%
The True Population Proportion Cure Rate is between 0.847 and 0.957 at a 95% confidence
interval for 121 children total with 101 being cured
27.
28.
29. Summary of Results to Date
112 patients
90.2% had no Parasites by the standard blood test
at
30-60 Days
Failures
All had Parasite content go to Zero
All were positive by Day 3o
Three of the failures were from one family
Clinical Standard of Practice Suggestion –
Repeat, Using adult dosage, no serum draws
30. NutraNanoSphere™ Malaria Formulation
● Simple, Oral Dose
● Drops are stable and completely water soluble
● Bioavailability for 8 nm NutraNanoSpheres™ > 90%
● Does not breakdown in the Stomach and Intestines
● Fast symptom relief – n=5
● Dramatic Clearance –
● No Recurrences –
● Inexpensive
● Can be used in capsules
31. NutraNano Sphere™ Malaria Formulation
● Fast symptom relief –
● Dramatic Clearance –
● No Recurrences – Projected
● Inexpensive -
● Can be used in capsules
Editor's Notes
Plasmodium falciparum (worst) also vivax, ovale, malariae